MyFinsight
Home
Blog
About
Contact
Download
Download image
Effect of exchange rate
change on cash and cash...
$46K
Net (decrease)
increase in cash and cash...
-$25,620K
Canceled cashflow
$46K
Stock-based compensation
$6,401K
Non-cash interest
expense - royalty...
$5,818K
German research and
development tax credit...
-$2,105K
Prepaid expenses and
other current assets
-$1,364K
Account payable
$1,260K
Change in fair value of
derivative liabilities -...
$394K
Accounts receivable
-$387K
Change in fair value of
derivative liabilities -...
$218K
Non-cash lease operating
expense
$62K
Proceeds from exercise of
stock options
$763K
Net cash used in
operating activities
-$25,006K
Net cash (used in)
provided by financing...
-$660K
Canceled cashflow
$18,009K
Canceled cashflow
$763K
Net loss
-$41,715K
Payment of transaction
costs in connection...
$1,269K
Accrued expenses and
other current...
-$1,300K
Deferred equity issuance
costs
$154K
Back
Back
Cash Flow
source: myfinsight.com
PALVELLA THERAPEUTICS, INC. (PVLA)
PALVELLA THERAPEUTICS, INC. (PVLA)